Influenza

Japanese pharmaceutical firms Astellas Pharma and UMN Pharma have released results for two Phase III clinical trials of the recombinant seasonal influenza HA vaccine ASP7374.

Out of the two trials, one enrolled 900 healthy volunteers aged from 20 to 64 years to compare the immunogenicity and safety of subcutaneously administered ASP7374 with approved egg-derived trivalent inactivated vaccine and to prove non-inferiority of ASP7374 to the egg-derived vaccine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This trial demonstrated non-inferiority of the recombinant seasonal influenza HA vaccine ASP7374 in comparison with the egg-based vaccine in terms of immunogenicity and no major safety problems were observed.

Astellas is carrying out this trial following the successfully completed clinical trial among 1,060 elderly volunteers.

Some 55 healthy volunteers aged 61 and over were enrolled in the second trial, which assessed the immunogenicity and safety of intramuscularly-administered ASP7374.

"The trial showed favourable immunogenicity and no major safety problem was observed."

The trial showed favourable immunogenicity and no major safety problem was observed.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The recombinant seasonal influenza HA vaccine ASP7374, which contains three different strains of antigens has been produced by a cell-culture manufacturing method using the Baculovirus Expression Vector System (BEVS), a next-generation technology platform for manufacturing biopharmaceutical products.

In January 2013, Protein Sciences secured approval of this vaccine from the US Food and Drug Administration (FDA).

According to the companies, the results of these clinical trials demonstrated favourable potential of the recombinant seasonal influenza HA vaccine ASP7374 produced by a cell-culture manufacturing method employing the BEVS.

Currently, the companies are preparing for the application for marketing approval of ASP7374 in Japan.

Image: a 3D model of an influenza virus. Photo: courtesy of Magnus Manske.